Validation of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson’s Disease
Objective: To assess the psychometric properties of the Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) in Parkinson’s disease (PD) across levels of cognitive abilities.…Prodromal symptoms in clinically diagnosed dementia with Lewy bodies stratified by Lewy body pathology on autopsy
Objective: Compare prodromal neuropsychiatric, sleep, and motor symptoms in patients clinically diagnosed with dementia with Lewy bodies (DLB) with and without Lewy body pathology on…Longitudinal CSF-profile and brain pathology mirrors clinical course of LRRK2-Related Parkinson’s Disease
Objective: Do clinical cognitive profiles and CSF characterisitcs of Abeta1_42, total-tau, phospho-tau and alpha-synuclein during lifetime correspond to histopathological findings post-mortem in LRKK2-associated Parkinson’s disease…Memantine induced dyskinesia in Alzheimer’s disease
Objective: There is only little evidence for memantine induced dyskinesia in Alzheimer’s disease. We present a patient with Alzheimer’s disease who developed choreatic dyskinesia as a result…Accuracy of the MoCA in Detecting PD-MCI in the Ontario Neurodegenerative Disease Research Initiative study
Objective: To investigate the ability of the Montreal Cognitive Assessment (MoCA) to detect mild cognitive impairment (MCI) in Parkinson’s disease (PD) using variations in cognitive…Encephalomyelopathy Due to Cerebrotendinous Xanthomatosis
Objective: To present a case in which the MRI of a patient with cerebrotendinous xanthomatosis (CTX) revelaled impairment of whole neuroaxis. Background: CTX is a…Higher probability of prodromal Parkinson’s disease is related to lower performance in all cognitive domains
Objective: to assess prodromal Parkinson disease (PD) probability and relate it to detailed cognitive performance in a community cohort. Background: There is a limited information…Antipsychotics Use in Parkinson’s Disease and Mortality Risks
Objective: To describe the use of antipsychotics in patients with Parkinson’s disease (PD) and study its associated mortality risks. Background: The US Food and Drug…SYN120 (a Dual 5-HT6/5-HT2A Antagonist) Study to Evaluate Safety, Tolerability and Efficacy in Parkinson’s Disease Dementia (SYNAPSE): Phase 2a Study Results
Objective: To evaluate the safety and preliminary efficacy of SYN120 in patients with Parkinson's disease dementia (PDD). Background: SYN120 is an antagonist of serotonin receptors…Interaction between MAPT H1 and APOE4 in early Parkinson’s Disease
Objective: To define if the high risk MAPT allele of rs393152 (H1 haplotype) is associated with differences in brain structure, clinical presentation, progression or cognitive…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 36
- Next Page »